Why the study?
Traditional lipid nanoparticles carrying mRNAs are thermodynamically unstable and require low-temperature storage, which hinders their widespread use for treating lung-associated diseases.
The development of FNPs offers a highly stable, lung-specific mRNA delivery platform that overcomes the cold-chain storage limitations of traditional LNPs.
No takes yet. Share an insight, caveat, or question.
May facilitate simplified mRNA storage and delivery; leaves open translation to human lung-targeted therapies.
Cao et al. (2022) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: